Get your full text copy in PDF

Nuclear matrix protein 22 (NMP 22) a tumour marker for detection of bladder cancer

Anton Oertl, Sandra Balan, Piotr K Okoński, Dietger Jonas, Gerhard M Oremek

Med Sci Tech 2007; 48(1): RA15-17

ID: 881540

The aim of this study was to evaluate the diagnostic power of nuclear matrix protein 22 (NMP22) for the detectiono f bladder cancer. 107 patients suffering from bladder cancer or suspected bladder cancer, patients with benignurological lesions (cystitis, pyelonephritis, urethritis, benign bladder tumour) were included. Freshly voided spot urine samples were taken for examination of NMP22 levels by enzyme-linked immunoassay. The sensitivity of the NMP22 test according to the tumour grading was: G1 – 38% (29%) (results of cytology in brackets), G2 – 52% (55%), G3 – 77% (70%). The specifity was 66,9% (80%). NMP22 is reliable for detecting bladder cancer. In benign lesions, such as cystitisorurinary tract infections lead to false positive results. (Clin Exp Med Lett 2007; 48(1):15-17)

Keywords: bladder carcinoma, benign urological lesions, nuclear matrix protein 22, Cytology

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

I agree